MedTrace Logo

Interleukin-6 Antagonists in Critically-ill Covid-19 Patients

NCT05218369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-04-20

No results posted yet for this study

Summary

The emerging SARS-COV2 virus has shed a new light on the cross-talks between the immune and the hemostatic system. In this study we aim to evaluate the dynamic change in coagulation caused by the modulation of the inflammatory response by interleukin-6 antagonist as assessed by viscoelastic methods in critically ill COVID-19 patients. Furthermore we try to draw attention to possible associations between the endothelial cell injury, inflammation and coagulation.

Conditions

Interventions

DRUG

IL6 Antagonist

Patients will receive IL-6 antagonist therapy at the consultant's discretion.

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-06
Primary Completion
2023-12-31
Completion
2024-12-01

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218369 on ClinicalTrials.gov